For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 445,512 | |||
| General and administrative | 3,315,433 | |||
| Asset impairment loss | 402,746 | |||
| Total operating expenses | 4,163,691 | |||
| Loss from operations | -4,163,691 | |||
| Interest expense, net | -24,406 | |||
| Change in fair value of contingent consideration and derivative financial instruments | -4,089,753 | |||
| Loss before income taxes | -8,277,850 | |||
| Net loss | -8,277,850 | |||
| Basic EPS | -0.88 | |||
| Diluted EPS | -0.88 | |||
| Basic Average Shares | 9,409,375 | |||
| Diluted Average Shares | 9,409,375 | |||
Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc. (HEPA)